| Literature DB >> 24330673 |
Hassan Momtaz1, Farhad Safarpoor Dehkordi, Mohammad Javad Hosseini, Meysam Sarshar, Maliheh Heidari.
Abstract
BACKGROUND: From a clinical perspective, it is important to know which serogroups, virulence genes and antibiotic resistance patterns are present in Shiga toxin-producing Escherichia coli strains in pediatric patients suffering from diarrheic and non-diarrheic infections. This is the first study in Iran that has comprehensively investigated the Shiga toxin-producing Escherichia coli -related infection characteristics in diarrheic and non-diarrheic pediatric patients of 0-60 months of age.Entities:
Year: 2013 PMID: 24330673 PMCID: PMC3866933 DOI: 10.1186/1757-4749-5-39
Source DB: PubMed Journal: Gut Pathog ISSN: 1757-4749 Impact factor: 4.181
Incidence of isolated from diarrheic and non-diarrheic children
| 52 | 36 (69.23%) | |
| 76 | 59 (77.63%) | |
| 39 | 24 (61.53%) | |
| 24 | 16 (66.66%) | |
| 33 | 19 (57.57%) | |
| 224 | 154 (68.75) | |
| 84 | 31 (36.90%) | |
| 308 | 185 (60.06%) |
Distribution of virulence factors in subtypes
| | Non detected | 12 (33.66%) | - |
| | EHEC | - | |
| | | | |
| | AEEC | 24 (66.66%) | |
| | | ||
| | | | |
| | | | |
| | Total | 36 (69.23%) | |
| | Non detected | 18 (30.50%) | - |
| | EHEC | 2 (3.38%) | |
| | | | |
| | AEEC | 39 (66.10%) | |
| | | ||
| | | | |
| | Total | 59 (77.63%) | |
| | Non detected | 6 (25.00%) | - |
| | EHEC | 1 (4.16%) | |
| | | | |
| | AEEC | 17 (70.83%) | |
| | | ||
| | | | |
| | Total | 24 (61.53%) | |
| | Non detected | 4 (25.00%) | - |
| | EHEC | | |
| AEEC | 12 (75.00%) | ||
| | | | |
| | | | |
| | Total | 16 (66.66%) | |
| | Non detected | 7 (36.84%) | - |
| | EHEC | 3 (15.78%) | |
| | | | stx1, eaeA, ehly: 3 (100%) |
| | AEEC | 9 (47.36%) | |
| | | stx1: 7 (77.77%) | |
| | | | stx2: 1 (11.11%) |
| eaeA: 6 (66.66%) | |||
| stx1, eaeA: 4 (44.44%) | |||
| stx2, eaeA: 4 (44.44%) | |||
| stx1, stx2, eaeA: 1 (11.11%) | |||
| | Total | 19 (57.57%) | |
| | Non detected | 16 (51.61%) | |
| | EHEC | | |
| | | | stx1, eaeA, ehly |
| | AEEC | 15 (48.38%) | |
| | | stx1: 12 (80.00%) | |
| | | | stx2: 2 (13.33%) |
| | | | eaeA: 13 (86.66%) |
| stx1, eaeA: 7 (46.66%) | |||
| stx2, eaeA: 6 (40.00%) | |||
| stx1, stx2, eaeA: 2 (13.33%) | |||
| Total | 31 (36.90%) |
Incidence of Shiga toxin-producing serogroups
| - | 7 | 2 | 5 | 2 | 1 | 3 | 2 | 1 | 1 | |
| 2 | 10 | 3 | 7 | 4 | 4 | 5 | 1 | 3 | 2 | |
| 1 | 4 | 2 | 3 | - | 1 | 3 | - | 4 | - | |
| - | 4 | - | - | 2 | 1 | 1 | - | 2 | 2 | |
| 3 | 2 | 1 | 2 | - | 1 | - | 1 | 1 | 1 | |
| - | 6 | - | 6 | - | 3 | - | - | - | - | |
| 6 (4.91%) | 33 (27.04%) | 8 (6.55%) | 23 (18.85%) | 8 (6.55%) | 11 (9.01%) | 12 (9.83%) | 4 (3.27%) | 11 (9.01%) | 6 (4.91%) |
Distribution of antimicrobial resistance genes in Shiga toxin-producing serogroups
| 2 | 2 | 2 | - | - | 2 | - | 4 | 2 | - | - | |
| 25 | 18 | 17 | 12 | 8 | 29 | 31 | 19 | 22 | 1 | - | |
| 4 | 8 | - | - | - | 3 | 2 | 5 | 4 | - | - | |
| 11 | 7 | 10 | 8 | 6 | 16 | 20 | 12 | 11 | - | - | |
| 4 | 6 | 4 | 6 | - | - | 8 | 6 | 3 | - | - | |
| 5 | 7 | 4 | 9 | - | 8 | 10 | 8 | 5 | - | - | |
| 5 | 6 | 5 | 4 | 1 | 11 | 10 | 8 | 6 | - | 1 | |
| 4 | 2 | 2 | - | - | 4 | 4 | 3 | 1 | - | - | |
| 9 | 6 | - | 4 | - | 7 | 10 | 4 | 3 | - | - | |
| 5 | 1 | 3 | 1 | - | 3 | 6 | - | 2 | - | - | |
| 74 (60.65%) | 63 (51.63%) | 47 (38.52%) | 44 (36.06%) | 15 (12.29%) | 83 (68.03%) | 101 (82.78%) | 69 (56.55%) | 59 (48.36%) | 1 (0.81%) | 1 (0.81%) |
Antimicrobial resistance properties in Shiga toxin-producing serogroups
| 4 | 2 | - | - | 2 | - | 3 | - | - | - | 2 | 6 | |
| 32 | 24 | 1 | 29 | 26 | 3 | 17 | - | 11 | 1 | 18 | 33 | |
| 8 | 3 | - | 1 | 3 | - | 4 | 1 | - | - | 2 | 8 | |
| 16 | 11 | - | 19 | 14 | 2 | 11 | 2 | 8 | - | 8 | 23 | |
| 8 | 4 | - | 8 | - | - | 4 | - | 4 | 1 | 2 | 8 | |
| 10 | 5 | - | 11 | 7 | 1 | 7 | - | 8 | - | 2 | 11 | |
| 10 | 4 | 1 | 8 | 10 | 1 | 6 | - | 4 | - | 6 | 12 | |
| 4 | - | - | 3 | 4 | - | 2 | - | - | - | 1 | 4 | |
| 9 | 9 | - | 10 | 7 | 1 | 2 | - | 3 | - | 3 | 11 | |
| 5 | 5 | - | 5 | 3 | - | - | - | 1 | - | - | 6 | |
| 106 (86.88%) | 67 (54.91%) | 2 (1.63%) | 94 (77.04%) | 76 (62.29%) | 8 (6.55%) | 56 (45.90%) | 3 (2.45%) | 39 (31.96%) | 2 (1.63%) | 44 (36.06%) | 122 (100%) |
*TE30 = tetracycline (30 μg/disk); S10 = (10 μg/disk); C30 = chloramphenicol (30 μg/disk); SXT = sulfamethoxazole (25 μg/disk); GM10 = gentamycin (10 μg/disk); NFX5 = enrofloxacin (5 μg/disk); CF30 = cephalothin (30 μg/disk); CIP5 = ciprofloxacin (5 μg/disk); TMP5 = trimethoprim (5 μg/disk); F/M300 = nitrofurantoin (300 μg/disk); AM10 = ampicillin (10 u/disk); P10 = penicillin (10 u/disk).
Seasonal distribution of serogroups and clinical signs in diarrheic children
| - | 9 | - | 3 | 5 | 6 | 2 | - | 5 | 2 | |
| 4 | 10 | 3 | 5 | 2 | 1 | 7 | 2 | 3 | 3 | |
| - | 2 | 3 | 9 | - | 1 | - | - | 1 | 1 | |
| 2 | 6 | 2 | - | 1 | - | 3 | 2 | 2 | - | |
| - | 7 | 1 | 6 | 5 | 5 | 5 | 3 | 7 | 3 | |
| 2 | 17 | 1 | 8 | - | 1 | 3 | 1 | 1 | - | |
| 4 | 3 | 1 | - | 2 | - | 2 | - | 1 | 1 | |
| - | - | 5 | 3 | 1 | 2 | 2 | - | 2 | 2 |
Distribution of antimicrobial resistance pattern of Shiga toxin producing in various clinical samples
| 33 (78.57) | 15 (35.71) | - | 28 (66.66) | 13 (30.95) | 1 (2.38) | 11 (26.19) | - | 9 (21.42) | - | 10 (23.80) | 42 (100) | |
| 34 (100) | 22 (64.70) | - | 32 (94.11) | 27 (79.41) | 2 (5.88) | 17 (50) | - | 10 (29.41) | - | 11 (32.35) | 34 (100) | |
| 14 (100) | 14 (100) | 1 (7.14) | 14 (100) | 14 (100) | 3 (21.42) | 12 (85.71) | 2 (14.28) | 11 (78.57) | 2 (14.28) | 13 (92.85) | 14 (100) | |
| 17 (100) | 12 (70.58) | 1 (5.88) | 16 (94.11) | 14 (82.35) | 2 (11.76) | 13 (76.47) | 1 (5.88) | 7 (41.17) | - | 7 (41.17) | 17 (100) | |
| 8 (53.33) | 4 (26.66) | - | 4 (26.66) | 8 (53.33) | - | 3 (20) | - | 2 (13.33) | - | 3 (20) | 15 (100) | |
| 106 (86.88%) | 67 (54.91%) | 2 (1.63%) | 94 (77.04%) | 76 (62.29%) | 8 (6.55%) | 56 (45.90%) | 3 (2.45%) | 39 (31.96%) | 2 (1.63%) | 44 (36.06%) | 122 (100%) | |